on MEDINCELL (EPA:MEDCL)
Record sales for UZEDY® in the second quarter of 2026
Medincell and its partner Teva Pharmaceuticals announced that net sales of UZEDY® in the United States reached $77 million for the second quarter of 2026. This represents a 43% increase year-over-year. As a result, Teva raised its annual sales forecast for UZEDY®, now estimating it to be between $270 million and $290 million.
UZEDY® is a long-acting injectable treatment for schizophrenia. Prescriptions increased by 63% year-over-year, driven by a rise in both prescribers and prescription volumes. Medincell receives royalties on net sales and could earn up to $105 million in commercial milestones.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MEDINCELL news